MOUNTAIN VIEW, Calif.,
March 30, 2015 /PRNewswire/
-- IRIDEX Corporation (Nasdaq:IRIX) today announced that the
United States Patent and Trademark Office granted the Company a
patent for a new proprietary disposable device intended to replace
certain suturing techniques in eye surgery. The iClip Closure
Device will initially be focused on trabeculectomies and is
intended to expand to a broader range of ophthalmic surgical
procedures in the future.
A trabeculectomy is a common surgical procedure used in the
treatment of glaucoma to drain fluid and relieve intraocular
pressure. During the procedure, a surgeon removes a piece of tissue
in the drainage angle of the eye allowing fluid to bypass the
clogged drainage channels. It is estimated that approximately
400,000 trabeculectomies are performed each year worldwide.
"Eye surgery is a very delicate and precise process," stated
co-inventor Steven Vold, MD,
cataract and glaucoma specialist. "The new iClip technology
is intended to drive efficiencies in multiple procedures with an
initial focus in glaucoma."
"The iClip is a product that has a broad array of potential
applications for eye surgery and is consistent with an integral
part of our strategic plan: developing products that provide us
new, recurring and therefore, predictable revenue streams," stated
Will Moore, IRIDEX President and
CEO. "Furthermore, we believe ongoing investment in
defensible intellectual property creates the opportunity for adding
significant shareholder value."
About IRIDEX
IRIDEX Corporation was founded in 1989
and is a worldwide leader in developing, manufacturing, and
marketing innovative and versatile laser-based medical systems,
delivery devices and consumable instrumentation for the
ophthalmology market. We maintain a deep commitment to the success
of our customers, with comprehensive technical, clinical, and
service support programs. IRIDEX is dedicated to a standard of
excellence, offering superior technology for superior results.
IRIDEX products are sold in the United
States through a direct sales force and internationally
through a combination of a direct sales force and a network of
approximately 70 independent distributors into over 100 countries.
For further information, visit the IRIDEX website at
http://www.iridex.com/.
Safe Harbor Statement
This announcement contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Act of 1934, as amended, including those statements
concerning potential applications for the iClip and other Company
products, changes in shareholder value, the protectability and
results of any future challenges to the Company's intellectual
property rights, the markets in which the Company operates, trends
in treatment and product usage, product plans and future product
releases, regulatory approvals, usage and efficacy of Company
products, future financial results and the Company's strategic
plans and objectives. These statements are not guarantees of future
performance and actual results may differ materially from those
described in these forward-looking statements as a result of a
number of factors. Please see a detailed description of these and
other risks contained in our Annual Report on Form 10-K for the
fiscal year ended December 28, 2013,
which was filed with the Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made
as of this date and will not be updated.
Logo - http://photos.prnewswire.com/prnh/20141001/149809
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/iridex-granted-us-patent-for-disposable-device-for-efficient-and-predictable-wound-closure-in-eye-surgeries-300057299.html
SOURCE IRIDEX Corporation